The treatment options for LM in NSCLC includes surgery, radiation for symptomatic or bulky disease, systemic and intrathecal chemotherapy, and targeted molecular therapies, including EGFR and ALK inhibitors, alongside immunotherapy [25]. Here, ALK is linked to non-small cell lung carcinoma.